| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
CyclophosphamideTNP470AngiostatinAcroleinSystemic lupus erythematosusAutoimmunityAldehyde dehydrogenaseLung (Toxicology)| 1 | 2004 | Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? | 
| + | - | nl | Neth J Med 62(10):347-52 (2004) |
| 2 | 2004 | Angiogenesis inhibition by angiostatin, endostatin and TNP-470 prevents cyclophosphamide induced cystitis. |
| + | - | nl | Angiogenesis 7(1):69-73 (2004) |
| 3 | 1997 | Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. |
| + | - | nl | Ann Rheum Dis 56(8):481-7 (1997) |
| 4 | 2000 | The molecular effects of acrolein. |
| + | - | nl | Toxicol Sci 57(1):6-15 (2000) |
| 5 | 2004 | Cyclophosphamide for severe lupus nephritis: where are we now? |
| + | - | nl | Arthritis Rheum 50(12):3748-50 (2004) |
| 6 | 2010 | Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. |
| + | - | nl | Arthritis Rheum 62(1):9-21 (2010) |
| 7 | 2009 | How did cyclophosphamide become the drug of choice for lupus nephritis? |
| + | - | nl | Nephrol Dial Transplant 24(2):381-4 (2009) |
| 8 | 2002 | High dose cyclophosphamide treatment for autoimmune disorders. |
| + | - | nl | ScientificWorldJournal 2(-):1808-15 (2002) |
| 9 | 2005 | Clinical significance of cyclophosphamide-induced cardiotoxicity. |
| + | - | nl | Intern Med 44(2):89-90 (2005) |
| 10 | 2003 | Cyclophosphamide-induced late-onset lung disease. |
| + | - | nl | Intern Med 42(1):82-7 (2003) |
| 11 | 2008 | Malignancies and cyclophosphamide exposure in Wegener's granulomatosis. | 
| + | - | nl | J Rheumatol 35(1):11-3 (2008) Bernatsky S |
